세계의 정맥혈전 색전증 시장 보고서(2025년)

Venous thromboembolism (VTE) is a medical condition marked by the development of blood clots within the veins, carrying the potential for serious or life-threatening complications. Common indicators of VTE encompass symptoms like leg pain and swelling, rapid breathing, chest discomfort, and more. Diverse treatment methods, including anticoagulant medications, medical devices, and thrombolytic therapy, are employed in managing VTE.

The primary categories of venous thromboembolism consist of deep vein thrombosis, pulmonary embolism, and other related conditions. Deep vein thrombosis (DVT) represents a medical condition characterized by the development of blood clots within the deep veins of the body. Treatment options encompass the use of anticoagulant medications, mechanical devices, thrombolytic therapy, and various other interventions. These treatments cater to diverse end-users, including hospitals, homecare settings, specialty centers, and other relevant healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The venous thromboembolism market research report is one of a series of new reports from The Business Research Company that provides venous thromboembolism market statistics, including venous thromboembolism industry global market size, regional shares, competitors with a venous thromboembolism market share, detailed venous thromboembolism market segments, market trends and opportunities and any further data you may need to thrive in the venous thromboembolism industry. This venous thromboembolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.44 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.

The forecast of 4.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. hospitals by driving up the cost of direct oral anticoagulants and mechanical thrombectomy devices sourced from Ireland and Belgium, exacerbating treatment costs and delaying life-saving interventions. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The expansion of healthcare infrastructure is expected to drive the growth of the venous thromboembolism (VTE) market. Healthcare infrastructure refers to the systems, institutions, policies, and resources that enable the delivery of medical care, including prevention, treatment, and rehabilitation services. The growing healthcare industry supports the implementation of VTE prevention protocols and the development of related treatments. For example, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the U.S., rising from 6,093 in 2022 to 6,129 in 2023. Similarly, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure, which reached £292 billion in 2023. Additionally, long-term health and social care expenditures rose by 2.8% in real terms in 2022. As healthcare systems expand, they will increasingly focus on VTE prevention, thus boosting the market for related products and services.

The growth of the venous thromboembolism market is further bolstered by the escalating number of orthopedic procedures. Orthopedic procedures encompass various surgical interventions used to address conditions affecting the spine, joints, and skeletal deformities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) are associated with a heightened risk of VTE, leading to an increased adoption of compression devices for DVT prophylaxis. Compression devices serve to prevent the formation of blood clots in the deep veins of the legs, mitigating the risk of venous thromboembolism (VTE). For instance, research published by the National Library of Medicine in February 2023 indicates that THA and TKA procedures are projected to rise significantly, with 1,222,988 and 719,364 procedures, respectively, anticipated by 2040. Moreover, TKAs are estimated to reach 2,917,959 by 2060, while THAs are projected to total 1,982,099 by that time. Consequently, the mounting number of orthopedic procedures is a significant driver of the venous thromboembolism market's growth.

Leading companies within the venous thromboembolism market are spearheading the development of innovative anticoagulant drugs and solutions to maintain their market positions. Advances in anticoagulants hold the potential to yield more effective drugs capable of preventing or treating venous thromboembolism. For example, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, secured regulatory approval for its abelacimab anticoagulant medication from the Food and Drug Administration (FDA). This fully human monoclonal antibody is indicated for stroke and systemic embolism prevention in atrial fibrillation patients. The newly developed abelacimab, a once-monthly dual-acting antibody, is designed to provide hemostasis-sparing anticoagulation by inhibiting Factor XI.

In August 2022, Boston Scientific Corporation, a US-based leader in surface modification technologies, acquired Obsidio, Inc., a US-based company specializing in biodegradable embolic materials for treating venous conditions, for an undisclosed amount. This acquisition strengthens Boston Scientific's portfolio of innovative therapies, expanding its capabilities in minimally invasive procedures aimed at patients with venous conditions. The acquisition is expected to enhance the company's offerings in the growing field of venous health, particularly with Obsidio's cutting-edge materials designed to improve treatment outcomes for patients suffering from conditions like venous thromboembolism (VTE).

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the venous thromboembolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The venous thromboembolism market consists of revenues earned by entities by providing services such as surgical assistance and thrombolytic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous thromboembolism market also includes the sales of heparin, apixaban, dabigatran, rivaroxaban, edoxaban and warfarin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Venous Thromboembolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on venous thromboembolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for venous thromboembolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The venous thromboembolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
• 2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
• 3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Deep Vein Thrombosis (DVT): Proximal DVT; Distal DVT; Asymptomatic DVT
• 2) By Pulmonary Embolism (PE): Acute PE; Chronic PE; Submassive PE
• 3) By Other Types: Thrombophlebitis; Superficial Vein Thrombosis; Post-Thrombotic Syndrome
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi-Aventis LLC.; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Eli Lilly and Co Ltd.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Limited; Otsuka Pharmaceutical Co. Ltd.; Menarini Group; Ipsen S.A.; Dr. Reddy's Laboratories Ltd.; Apotex Inc.; Hikma Pharmaceuticals PLC; Cipla Inc.; Endo International plc; Aspen Pharmacare Holdings Limited; Zydus Lifesciences Ltd.; LEO Pharma A/S; Lupin Limited; Torrent Pharmaceuticals Ltd.; Almirall S.A.; Glenmark Pharmaceuticals Ltd.; Portola Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Venous Thromboembolism Market Characteristics

3. Venous Thromboembolism Market Trends And Strategies

4. Venous Thromboembolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Venous Thromboembolism Growth Analysis And Strategic Analysis Framework

• 5.1. Global Venous Thromboembolism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Venous Thromboembolism Market Growth Rate Analysis
• 5.4. Global Venous Thromboembolism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Venous Thromboembolism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Venous Thromboembolism Total Addressable Market (TAM)

6. Venous Thromboembolism Market Segmentation

• 6.1. Global Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deep Vein Thrombosis
• Pulmonary Embolism
• Other Types
• 6.2. Global Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Clotting Medications
• Mechanical Devices
• Thrombolytic Therapy
• Other Treatment
• 6.3. Global Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End Users
• 6.4. Global Venous Thromboembolism Market, Sub-Segmentation Of Deep Vein Thrombosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proximal DVT
• Distal DVT
• Asymptomatic DVT
• 6.5. Global Venous Thromboembolism Market, Sub-Segmentation Of Pulmonary Embolism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute PE
• Chronic PE
• Submassive PE
• 6.6. Global Venous Thromboembolism Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thrombophlebitis
• Superficial Vein Thrombosis
• Post-Thrombotic Syndrome

7. Venous Thromboembolism Market Regional And Country Analysis

• 7.1. Global Venous Thromboembolism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Venous Thromboembolism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Venous Thromboembolism Market

• 8.1. Asia-Pacific Venous Thromboembolism Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Venous Thromboembolism Market

• 9.1. China Venous Thromboembolism Market Overview
• 9.2. China Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Venous Thromboembolism Market

• 10.1. India Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Venous Thromboembolism Market

• 11.1. Japan Venous Thromboembolism Market Overview
• 11.2. Japan Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Venous Thromboembolism Market

• 12.1. Australia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Venous Thromboembolism Market

• 13.1. Indonesia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Venous Thromboembolism Market

• 14.1. South Korea Venous Thromboembolism Market Overview
• 14.2. South Korea Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Venous Thromboembolism Market

• 15.1. Western Europe Venous Thromboembolism Market Overview
• 15.2. Western Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Venous Thromboembolism Market

• 16.1. UK Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Venous Thromboembolism Market

• 17.1. Germany Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Venous Thromboembolism Market

• 18.1. France Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Venous Thromboembolism Market

• 19.1. Italy Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Venous Thromboembolism Market

• 20.1. Spain Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Venous Thromboembolism Market

• 21.1. Eastern Europe Venous Thromboembolism Market Overview
• 21.2. Eastern Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Venous Thromboembolism Market

• 22.1. Russia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Venous Thromboembolism Market

• 23.1. North America Venous Thromboembolism Market Overview
• 23.2. North America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Venous Thromboembolism Market

• 24.1. USA Venous Thromboembolism Market Overview
• 24.2. USA Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Venous Thromboembolism Market

• 25.1. Canada Venous Thromboembolism Market Overview
• 25.2. Canada Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Venous Thromboembolism Market

• 26.1. South America Venous Thromboembolism Market Overview
• 26.2. South America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Venous Thromboembolism Market

• 27.1. Brazil Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Venous Thromboembolism Market

• 28.1. Middle East Venous Thromboembolism Market Overview
• 28.2. Middle East Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Venous Thromboembolism Market

• 29.1. Africa Venous Thromboembolism Market Overview
• 29.2. Africa Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Venous Thromboembolism Market Competitive Landscape And Company Profiles

• 30.1. Venous Thromboembolism Market Competitive Landscape
• 30.2. Venous Thromboembolism Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Venous Thromboembolism Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi-Aventis LLC.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc.
• 31.5. Eli Lilly and Co Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sun Pharmaceutical Industries Limited
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Menarini Group
• 31.12. Ipsen S.A.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Apotex Inc.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Venous Thromboembolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Venous Thromboembolism Market

34. Recent Developments In The Venous Thromboembolism Market

35. Venous Thromboembolism Market High Potential Countries, Segments and Strategies

• 35.1 Venous Thromboembolism Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Venous Thromboembolism Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Venous Thromboembolism Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer